MariMed Q2 Revenue Hits Record $41.9M, Beats Estimates
MRMD is trading near its 52-week low of $0.061 (5.0% above the low).
Summary
MariMed posted record Q2 revenue of $41.9M, beating the single-analyst consensus of $39.8M, driven by gains in both wholesale and retail segments. Adjusted net loss narrowed to $2.4M versus the $3.9M expected, though adjusted EBITDA of $3.9M slightly missed the $4M estimate. Gross margin came in at 39%, with adjusted gross margin at 40%. Branded product distribution reached 85% of available storefronts, and loyalty program membership rose 14% year-to-date. The stock trades near its 52-week low at $0.064, so the revenue beat and narrower loss could provide a modest positive catalyst, but margin pressure and a wider net loss versus last year temper enthusiasm. This follows the 8-K filed earlier today that highlighted record revenue but also a wider net loss and lower adjusted EBITDA.
At the time of this announcement, MRMD was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $25.6M. The 52-week trading range was $0.06 to $0.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.